The Management of female voiding dysfunction patients who have underlying neurologic diseases with alfuzosin monotherapy

Non-Moderated Poster Session

12:30 PM - 1:30 PM

MD, PhD Duk Yoon Kim (1)

(1) Catholic University Of Daegu, Daegu, South Korea

Female voiding dysfunction (VD) is commonly affected and have a significant negative impact on health-related quality of life. Most of female VD might be related to detrusor underactivity or/and bladder out let obstruction. Voiding and storage symptoms can coexist, making the management challenging. In this study, we try to investigate the effects of alpha-blocker monotherapy with alfuzosin for the mild to moderate symptomatic female VD patients for 3 months follow-up.

AIMS

The 50 patients were enrolled. Inclusion criteria are as follows: 1) age above 18 years old and below 80 years old, 2) International Prostate Symptom Score (IPSS) over 8, 3) maximal flow rate (Qmax) below 25ml/sec, 4) no medication history of alpha-blockers, antimuscarinics and cholinergic drugs. The patient was enrolled two groups; group 1 (gr. 1) who do not have history of neurologic diseases, groups 2 (gr. 2) who have underlying neurologic diseases. The patient number in gr. 1 was 33, gr. 2 was 17. The mean age of gr. 1 was 57.7±11.5 and gr. 2 was 61.09±12.92 year-old. Underlying neurologic diseases are spinal stenosis 6, herniated nucleus pulposus (HNP) 2, cerebral infarction 2, peripheral neuropathy 3, Parkinson’s disease 3, brain tumor 1. Voiding dysfunction was evaluated with maximal uroflow rate (Qmax), post-void residual urine (PVR) and IPSS/quality of life (QoL). The measurement of these parameters was done at baseline, 1 month and 3 months follow-up after medication with alfuzosin 10mg.

METHODS

Mean value of Qmax was approximately 12ml/sec, PVR was approximately 60mL and IPSS was approximately 20 at baseline and most parameters improved statistically at 1 month, 3 months later. Table 1 and Figure 1,2,3 described the results.

RESULTS

Although a complete recovery from various conditions of female VD is not easy to achieve, alpha-blocker monotherapy can relieve the symptoms and decrease PVR in patients with/without neurologic diseases. So, it can improve life quality, minimise the long-term complications and applicable in outpatients approach.

CONCLUSIONS